Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

Masafumi Nakamura, Hiroshi Nakashima, Toshiya Abe, Takaaki Ensako, Koji Yoshida, Keisuke Hino

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

Original languageEnglish
Pages (from-to)3125-3130
Number of pages6
JournalAnticancer research
Issue number6
Publication statusPublished - Jun 1 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer'. Together they form a unique fingerprint.

Cite this